Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Oxular Limited
Oxford, England, United Kingdomoxular.com ↗
- Ownership
- Private
- Employees
- ~20
- Development stage
- Other
01
Overview
In October 2024, Oxular began dosing patients in the OXEYE phase 2 clinical trial, evaluating the safety, efficacy, and durability of OXU-001 in patients with diabetic macular edema. The trial is designed to evaluate a single suprachoroidal administration of OXU-001 over 52 weeks. Past and current trials indicate up to 12-month durability, sustained vision gain, and retinal thickness reduction.
- Therapeutic areas
- Ophthalmology
- Modalities
- Drug/device combination treatmentssustained-release formulations (Oxuspheres)
- Industry
- Biotech
Beyond the preview
Go deeper on Oxular Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oxular Limited.